-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 29, the Shanghai Sunshine Collection Network issued a "Notice on the Online Purchase of Newly-added Medical Insurance Negotiation Drugs in Some Countries (Second Batch)", which included three national pharmaceutical companies such as Hengrui Medicine and Shandong Buchang.
Talk about large varieties
.
According to the notice, some countries’ newly-added medical insurance negotiation drug online procurement will be pushed to hospitals by the "Shanghai Medical Purchasing Service and Supervision Information System" on December 29, 2021, and will take effect on January 1, 2022
.
Hanging on drug procurement accordance with current regulations, specific products, including Hengrui Medicine Park Pa ethanolamine sea song sheet, Shandong step pharmaceutical Xuanfei Baidu Granule, Santen Pharmaceutical of tafluprost ophthalmic solution and so on
.
Among them, Hengrui Medicine's Hytrapopopag ethanolamine tablets, a category 1 innovative drug independently developed by Hengrui Medicine, was officially approved for listing in June this year
.
The drug is a thrombopoietin receptor agonist (TPO-RA) approved for the indication of severe aplastic anemia (SAA) in China.
The currently approved indication is: the past has not responded to treatments such as glucocorticoids and immunoglobulins.
The best adult patients with chronic primary immune thrombocytopenia (ITP) and SAA adult patients with poor efficacy of immunosuppressive therapy (IST)
.
Hytrobopalpa is an oral administration mode, which changes the treatment mode that patients with chronic primary immune thrombocytopenia need to go to the hospital for injections regularly, bringing more freedom of life and treatment comfort to patients
.
At present, Hetropopaethanolamine tablets are still related to the treatment of initial treatment of non-severe/severe aplastic anemia (NSAA/SAA), childhood ITP/chemotherapy-induced thrombocytopenia (CIT), severe infections, and chronic liver disease-induced thrombocytopenia.
Research and explore further, the future can be expected
.
Shandong Buchang Pharmaceutical's Xuanfeibaidu Granules were approved for listing by the State Drug Administration through a special approval procedure on March 2, 2021
.
It is reported that the technology and prescription of Xuanfeibaidu Granules complies with the standard of making traditional Chinese medicine decoctions, combined with modern granule technology, with high content of active ingredients and easy to take.
.
According to the industry, the birth of Xuanfeibaidu Granules not only conforms to the guiding principles of the basic theories of Chinese medicine, but also passed the screening of the network pharmacology of the Chinese medicine component library of Tianjin University of Chinese Medicine.
At the same time, it adopts modern production and extraction technology, which is Chinese medicine + technology.
。The product .
It is understood that Buchang Pharmaceuticals has always attached great importance to scientific research and product development, insisted on technological innovation, actively created modern Chinese medicine, highlighted the research and development of innovative drugs and new drugs with independent intellectual property rights, and enhanced the company's core competitiveness
.
Santen Pharmaceutical's tafluprost eye drops is a new type of preservative-free prostaglandin analog (PGA) eye drops, which is clinically used to reduce open-angle glaucoma or high eyes in patients with elevated intraocular pressure Hypertension is also the first-line recommended medication in the glaucoma treatment guidelines
.
According to the industry, the new listing of these drugs will undoubtedly bring new medication options to more patients
.
According to the notice, after the release of the drug information, each drug manufacturer is asked to check the drug information of its own company.
If there is any doubt, it should promptly report the situation to the Shanghai Pharmaceutical Affairs Office
.
Talk about large varieties
.
According to the notice, some countries’ newly-added medical insurance negotiation drug online procurement will be pushed to hospitals by the "Shanghai Medical Purchasing Service and Supervision Information System" on December 29, 2021, and will take effect on January 1, 2022
.
Hanging on drug procurement accordance with current regulations, specific products, including Hengrui Medicine Park Pa ethanolamine sea song sheet, Shandong step pharmaceutical Xuanfei Baidu Granule, Santen Pharmaceutical of tafluprost ophthalmic solution and so on
.
Among them, Hengrui Medicine's Hytrapopopag ethanolamine tablets, a category 1 innovative drug independently developed by Hengrui Medicine, was officially approved for listing in June this year
.
The drug is a thrombopoietin receptor agonist (TPO-RA) approved for the indication of severe aplastic anemia (SAA) in China.
The currently approved indication is: the past has not responded to treatments such as glucocorticoids and immunoglobulins.
The best adult patients with chronic primary immune thrombocytopenia (ITP) and SAA adult patients with poor efficacy of immunosuppressive therapy (IST)
.
Hytrobopalpa is an oral administration mode, which changes the treatment mode that patients with chronic primary immune thrombocytopenia need to go to the hospital for injections regularly, bringing more freedom of life and treatment comfort to patients
.
At present, Hetropopaethanolamine tablets are still related to the treatment of initial treatment of non-severe/severe aplastic anemia (NSAA/SAA), childhood ITP/chemotherapy-induced thrombocytopenia (CIT), severe infections, and chronic liver disease-induced thrombocytopenia.
Research and explore further, the future can be expected
.
Shandong Buchang Pharmaceutical's Xuanfeibaidu Granules were approved for listing by the State Drug Administration through a special approval procedure on March 2, 2021
.
It is reported that the technology and prescription of Xuanfeibaidu Granules complies with the standard of making traditional Chinese medicine decoctions, combined with modern granule technology, with high content of active ingredients and easy to take.
.
According to the industry, the birth of Xuanfeibaidu Granules not only conforms to the guiding principles of the basic theories of Chinese medicine, but also passed the screening of the network pharmacology of the Chinese medicine component library of Tianjin University of Chinese Medicine.
At the same time, it adopts modern production and extraction technology, which is Chinese medicine + technology.
。The product .
It is understood that Buchang Pharmaceuticals has always attached great importance to scientific research and product development, insisted on technological innovation, actively created modern Chinese medicine, highlighted the research and development of innovative drugs and new drugs with independent intellectual property rights, and enhanced the company's core competitiveness
.
Santen Pharmaceutical's tafluprost eye drops is a new type of preservative-free prostaglandin analog (PGA) eye drops, which is clinically used to reduce open-angle glaucoma or high eyes in patients with elevated intraocular pressure Hypertension is also the first-line recommended medication in the glaucoma treatment guidelines
.
According to the industry, the new listing of these drugs will undoubtedly bring new medication options to more patients
.
According to the notice, after the release of the drug information, each drug manufacturer is asked to check the drug information of its own company.
If there is any doubt, it should promptly report the situation to the Shanghai Pharmaceutical Affairs Office
.
